Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis

PLoS One. 2022 Mar 31;17(3):e0266092. doi: 10.1371/journal.pone.0266092. eCollection 2022.

Abstract

Background: We have previously shown that transthyretin (TTR) amyloidosis patients have amyloid fibrils of either of two compositions; type A fibrils consisting of large amounts of C-terminal TTR fragments in addition to full-length TTR, or type B fibrils consisting of only full-length TTR. Since type A fibrils are associated with an older age in ATTRVal30Met (p.Val50Met) amyloidosis patients, it has been discussed if the TTR fragments are derived from degradation of the amyloid deposits as the patients are aging. The present study aimed to investigate if the fibril composition type changes over time, especially if type B fibrils can shift to type A fibrils as the disease progresses.

Material and methods: Abdominal adipose tissue biopsies from 29 Swedish ATTRVal30Met amyloidosis patients were investigated. The fibril type in the patients´ initial biopsy taken for diagnostic purposes was compared to a biopsy taken several years later (ranging between 2 and 13 years). The fibril composition type was determined by western blot.

Results: All 29 patients had the same fibril composition type in both the initial and the follow-up biopsy (8 type A and 21 type B). Even patients with a disease duration of more than 12 years and an age over 75 years at the time of the follow-up biopsy had type B fibrils in both biopsies.

Discussion: The result clearly shows that the amyloid fibril composition containing large amounts of C-terminal fragments (fibril type A) is a consequence of other factors than a slow degradation process occurring over time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Fat / metabolism
  • Aged
  • Aging / pathology
  • Amyloid Neuropathies, Familial* / metabolism
  • Amyloid* / metabolism
  • Humans
  • Prealbumin / metabolism

Substances

  • Amyloid
  • Prealbumin

Supplementary concepts

  • Amyloidosis, Hereditary, Transthyretin-Related

Grants and funding

This work was supported by: FAMY-Norrbotten, FAMY-Västerbotten och the AMYL foundation, https://www.famy.se/ and https://www.famynorrbotten.se/sv-SE (IA, EI, OBS); Erik, Karin and Gösta Selanders Foundation, https://www.stiftelsemedel.se/erik-karin-och-gsta-selanders-stiftelse/ (EI); the P.O. Zetterling Foundation, https://www.uaf.se/stiftelse/?s=91271 (EI); Swedish Heart and Lung foundation, grant no. 20160787, https://www3.hjart-lungfonden.se/ (OBS); the Swedish Research Council, grant no. 2019-01338, https://www.vr.se (JW, BP, IA); the Knut and Alice Wallenberg foundation, https://kaw.wallenberg.org/ (IA); Research grants from the Region of Västerbotten, https://regionvasterbotten.se/forskninghttp-adress (JW, BP, IA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.